Prognostic factors and clinical outcomes of breast cancer patients with disease progression during neoadjuvant systemic therapy
-
Published:2023-08
Issue:
Volume:70
Page:63-69
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Ling Yun-xiao,
Xie Yi-fan,
Wu Huai-liang,
Wang Xiao-fang,
Ma Jin-li,
Fan Lei,
Liu Guang-yuORCID
Subject
General Medicine,Surgery
Reference46 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;Ca - Cancer J Clin,2021
2. Breast cancer: current molecular therapeutic targets and new players;Nagini;Anti Cancer Agents Med Chem,2017
3. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020
4. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomized, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020
5. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomized, double-blind, phase 3 trial;Mittendorf;Lancet,2020